Oisin will follow later this year or in 2018, if they keep to the standard way in which things work in biotech companies following an A round.
I have no idea what SIWA will be doing; they have been around on life support for a while, and now resurrected by the newfound money coming into the field. I'd imagine that their next step would be some form of trial, though it is unclear as to where exactly they are in their animal study schedule.
There are people self-experimenting with senolytic drug candidates now, though not in any way that will provide useful data. If you draw the line at candidates for which there is in vivo evidence in mammals, you're left with just the chemotherapeutics and foxo4-dri. (A pity that fisetin has no in vivo evidence yet...). The chemotherapeutics are worth skipping over, since they are ugly chemicals and really only a starting point for the development of analogs without the horrible side-effects, and foxo4-dri hasn't been tested in any formal way in humans yet.
At the pace at which new drug candidates are emerging and being tested, a couple of years from now would be a good time to be self-experimenting.
See for example these entities working on means to selectively remove senescent cells, with Unity Biotechnolgy being the one connected to Buck Institute researchers:
https://oisinbio.com/
http://unitybiotechnology.com/
http://www.siwatherapeutics.com/
The presence of senescent cells have been shown to directly cause failure of regeneration, fibrosis, fibrotic lung diseases, loss of tissue elasticity, blood vessel calcification, faster progression of atherosclerosic lesions, arthritis, chronic inflammation, immune system dysfunction, and retinal degeneration, just to name a few items from papers published in the past two years. More links are being established in research papers with each passing year. The removal of these cells has been shown in mouse studies to quickly reverse the age-related progression of many of these items.